Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
Summary not available.
DexCom, Inc. (NASDAQ:DXCM) announced that its new Dexcom ONE Continuous Glucose Monitoring System will launch in the UK this May. Currently under review for addition to the NHS Drug Tariff, this system aims to enhance accessibility for diabetes management. The NICE has recommended offering glucose sensors to Type 1 diabetes patients based on individual needs, promoting better health outcomes. Dexcom ONE features a user-friendly app for real-time glucose monitoring, reducing the need for fingerpricks and improving treatment decisions.
DexCom, Inc. (NASDAQ:DXCM) announced plans to release its first quarter 2022 financial results after the market closes on Thursday, April 28, 2022. A conference call will be held at 4:30 p.m. (ET) to discuss the results, with a live webcast available on the investor relations website.
DexCom, based in San Diego, California, is a leader in continuous glucose monitoring systems, aiming to improve diabetes management globally.
Dexcom, Inc. (NASDAQ:DXCM) announced a four-for-one forward stock split, pending stockholder approval for an increase in authorized shares from 200 million to 800 million. If approved, each share outstanding on May 19, 2022, will split into four shares. The split-adjusted trading is set to commence on June 10, 2022. This action aims to enhance stock liquidity and accessibility for investors. Further details will be provided in the Preliminary Proxy Statement filed with the U.S. Securities and Exchange Commission on March 25, 2022.
DexCom (NASDAQ:DXCM) has received CE Mark approval for its Dexcom G7 Continuous Glucose Monitoring (CGM) system, enhancing diabetes management for users aged two and older in Europe. The Dexcom G7 features the market's fastest sensor warmup at 30 minutes, a compact design, and a redesigned mobile app that integrates Dexcom Clarity. This system eliminates the need for fingersticks, providing real-time glucose data directly to smart devices. DexCom plans to launch the G7 in Europe shortly, further solidifying its leadership in real-time CGM technology.
Dexcom announced CE Mark approval for its G7 Continuous Glucose Monitoring (CGM) System, enhancing diabetes management for users in Europe aged two years and older, including pregnant women. The G7 is designed to be more powerful and user-friendly, with a 30-minute sensor warmup time, no fingersticks required, and real-time glucose readings sent to compatible devices. The system reduces blood sugar fluctuations and increases time in range, supporting better health outcomes.
Dexcom, Inc. (NASDAQ: DXCM) received approval from the Ontario government for coverage of its Dexcom G6 CGM System through the Assistive Devices Program, effective March 14, 2022. This initiative benefits individuals with type 1 diabetes over the age of 2 who meet specific criteria, expanding access to this innovative glucose monitoring technology. Ontario joins six other provinces in offering public coverage for continuous glucose monitoring, enhancing diabetes management and potentially reducing long-term health complications.
Dexcom (NASDAQ:DXCM) has received Breakthrough Device Designation from the FDA for its continuous glucose monitoring (CGM) system, aimed at improving glycemic management in hospital settings. This designation accelerates the regulatory review process, enabling faster market access for the technology. In prior studies involving over 800 patients during the pandemic, Dexcom CGM demonstrated enhanced glucose control without increased hypoglycemia risk. Experts anticipate that this designation will significantly advance in-patient care capabilities.
DexCom, Inc. (NASDAQ:DXCM) announced upcoming presentations at virtual investor conferences. Brice Bobzien, Vice President of Finance, will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 5:00 PM (EST). Jereme Sylvain, Executive Vice President and CFO, will present at the Citi 2022 Healthcare Services Conference on February 23, 2022, at 10:15 AM (EST). Webcast links will be available on the Dexcom Investor Relations website, where they will also be archived for future access.
DexCom, Inc. (Nasdaq: DXCM) reported Q4 2021 revenue of $698.2 million, a 23% increase year-over-year, with U.S. growth at 15% and international at 54%. Full year revenue rose 27% to $2.45 billion. However, GAAP operating income fell sharply to $0.6 million, a decline of 1,820 basis points compared to Q4 2020. The company reiterated its 2022 revenue guidance of $2.82 - 2.94 billion. DexCom aims for a strong market position with the upcoming G7 CGM System and emphasized improved access to diabetes technology.